Roundtable Roundup April: Renal Cell Carcinoma
In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with clear cell renal cell carcinoma (RCC) and why they would make that choice.
CASE SUMMARY
- An African American woman aged 59 years presented with a left renal mass.
- She underwent left radical nephrectomy, which revealed clear cell RCC.
- Nine months later, she developed nodules in both lungs, mediastinum (35 × 38 mm), and retroperitoneal lymph nodes.
- Lung biopsy confirmed stage IV RCC with clear cell histology.
- Karnofsky performance status: 90%
- Hemoglobin: 11.1 g/dL
- Corrected calcium, neutrophils, and platelets: within normal limits
POLLING QUESTION
A decision was made to initiate systemic therapy. What frontline therapy are you most likely to choose for this patient?
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More
